Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular DiseaseThe Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee

被引：0
作者：
E. Magnus Ohman
Christopher B. Granger
Lawrence Rice
Charles S. Abrams
Richard C. Becker
Peter B. Berger
Neal S. Kleiman
David Moliterno
Stephan Moll
Jo E. Rodgers
Stephen S. Steinhubl
Victor F. Tapson
Peter Sinnaeve
Kevin J. Anstrom
机构：
[1] University of North Carolina,Division of Cardiology, Division of Hematology, and School of Pharmacy
[2] Duke University Medical Center,Division of Cardiology, Division of Pulmonary Medicine and Duke Clinical Research Institute
[3] University of Pennsylvania School of Medicine,Hematology
[4] University of Kentucky,Oncology Section and Section of Cardiology, Baylor College of Medicine and Methodist Hospital, Houston, TX; 4Hematology/Oncology Division
[5] UNC-Chapel Hill,Division of Cardiovascular Medicine
来源：
Journal of Thrombosis and Thrombolysis | 2005年 / 19卷
关键词：
heparin; thrombosis; thrombocytopenia; registry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Heparin-induced thrombocytopenia (HIT) is estimated to occur in 1–5% of all patients receiving heparin, and 25–50% of such cases develop heparin-induced thrombocytopenia with thrombosis (HITT) A conservative estimate based only on cardiovascular patients suggests that in the United States approximately 100,000 patients develop thrombocytopenia, and 25–50,000 develop HITT annually. Both HIT and HITT are associated with high morbidity and mortality and represent substantial worldwide public health concerns.
引用
收藏
页码：11 / 19
页数：8
相关论文
共 116 条
  • [21] Scharfman WB(2002)Recombinant hirudin in clinical practice: Focus on lepirudin Catheter Cardiovasc Interv 57 177-184
  • [22] Bell WR(2002)Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia Postgrad Med 112 85-89
  • [23] Tomasulo PA(2002)Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes Blood Reviews 16 77-80
  • [24] Alving BM(2001)Heparin-induced thrombocytopenia: An overview Blood 98 2442-2447
  • [25] Duffy TP(1995)Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA Thromb Haemost 73 21-28
  • [26] Bell WR(1994)Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases J Am Coll Cardiol 23 891-898
  • [27] Royall RM(2001)for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction Circulation 103 643-650
  • [28] Rhodes GR(1998)Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation J Am Coll Cardiol 32 311-319
  • [29] Dixon RH(1997)RM for the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization Circulation 95 809-813
  • [30] Silver D(2000)Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy Am Heart J 140 74-80
12345678910